Fenton Mary Kay 4

What Happened Mary Kay Fenton, Chief Financial Officer of Cullinan Therapeutics (CGEM), was granted a total of 206,250 shares on 2026-02-18 through company awards. The filing shows two award entries: 68,750 shares reported as a restricted stock unit award (acquired at $0.00) and 137,500 shares reported as a derivative award/option (acquired at $0.00). The reported dollar amount paid for these awards is $0.00 — these are compensation grants, not open-market purchases.

Key Details

• Transaction date: 2026-02-18; Form 4 filed 2026-02-19 (filed within the standard 2-business-day window).
• Grants reported:
  • 68,750 shares — Award/RSU — $0.00 per share (Footnote F1).
  • 137,500 shares — Award/Derivative (option) — $0.00 per share (Footnote F2).
• Shares owned after the transactions: not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: RSUs vest annually over four years.
  • F2: Option/derivative vests over four years, with 1/48th vesting monthly until the fourth anniversary.
• Transaction code: A (award/grant); derivative award noted for the option grant.

Context These entries reflect compensation awards (restricted stock units and an option-style grant) that will vest over time under Cullinan’s equity compensation schedules. Such awards are common executive compensation and do not by themselves indicate immediate buying or selling activity in the market. The option/derivative portion will vest monthly over four years per the footnote; any future exercise or sale would be reported separately.